b'B:17"T:16.5"S:15.5"Therst and only sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC) in adults 1ANOTHER DAY IS DAWNINGIN THE CONTROL OF UCNow many of your patients can choose another path forward before biologics. 1aZEPOSIAdelivers: Lasting Remission 1 Demonstrated One Capsule, Signi cantly higher clinicalSafety Pro le 1b Once Daily 1remission rates vs placeboStudied in 4 clinical trials Once-daily oral in the pivotal trial:with over 1370 ZEPOSIA- administration, with 18% (79/429) vs 6% (13/216)treated patients acrossor without foodat Week 10 (p0.0001) andmultiple indications37% (85/230) vs 19% (42/227) at Week 52 (p0.0001)ae patients at Week 10 ZEPOSIA demonstrated higher rates of clinical remission vs placebo in tumor necrosis factor inhibitor (TNFi)-nav(22% [66/299] vs 7% [10/151]) and at Week 52 (41% [63/154] vs 22% [35/158], respectively) 1.In UC Study 1 and UC Study 2, of the ZEPOSIA-treated patients who were TNFi-nave, 288 and 145 were also biologic nave, respectively.2Ef cacy analysis by prior TNFi therapy was prespeci ed, but not powered to detect a difference in the treatment effect in these subgroups.3Visit ZEPOSIAHCP.COM/UC to learn moreS:9.875" T:10.875" B:11.375"bZEPOSIA has been studied across multiple indications in 4 clinical trials including TRUE NORTH (NCT02435992), a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial; TOUCHSTONE (NCT01647516), a randomized, double-blind, placebo-controlled phase 2 clinical trial; and SUNBEAM (NCT02294058) and RADIANCE (NCT02047734), 2 multicenter, randomized, double-blind, double-dummy, active treatment-controlled phase 3 clinical trials. 496 patients receiving the 0.92-mg dose of ZEPOSIA during induction in TRUE NORTH or TOUCHSTONE and 882 patients receiving the 0.92-mg dose of ZEPOSIA in SUNBEAM or RADIANCE were assessed in the safety analysis 1 .Clinical Trial: The ef cacy and safety of ZEPOSIA were evaluated in two multicenter, randomized, double-blind, placebo-controlled clinical studies [UC Study 1 (induction) and UC Study 2 (maintenance)] in adult patients with moderately to severely active ulcerative colitis, de ned as a Mayo score of 6 to 12 at baseline. 1Primary Endpoint of Clinical Remission Is De ned as: rectal bleeding subscore (RBS)=0, stool frequency subscore (SFS) 0 or 1 (and aIMPORTANT SAFETY INFORMATION (cont\'d)decrease of 1 point from baseline SFS), and endoscopy subscore 0 or 1 without friability.1 Infections: (cont\'d)UC Study 1 (10-week induction): 645 patients were randomized 2:1 to either ZEPOSIA 0.92 mg given orally once daily or placebo for 10 weeks, beginning with a dosage titration. The trial included patients who had an inadequate response or were intolerant to any of theHerpes zoster was reported as an adverse reaction in ZEPOSIA-treated patients. Herpes simplex encephalitis following: oral aminosalicylates, corticosteroids, immunomodulators, or a biologic. Patients were required to be on stable doses of oraland varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. aminosalicylates and/or corticosteroids. 1 Patientswithoutahealthcareprofessional-con rmedhistoryofvaricella(chickenpox),orwithout UC Study 2 (42-week maintenance): 457 patients who received ZEPOSIA in either UC Study 1 or in an open-label arm anddocumentationofafullcourseofvaccinationagainstvaricellazostervirus(VZV),shouldbetestedfor achieved clinical response at Week 10 were re-randomized 1:1 and were treated with either ZEPOSIA 0.92 mg (n=230) or placebo (n=227) for 42 weeks (UC Study 2), for a total of 52 weeks of treatment. 1 antibodies to VZV before initiating ZEPOSIA. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ZEPOSIAINDICATION Cases of fatal cryptococcal meningitis (CM) were reported in patients treated with another S1P receptor ZEPOSIA (ozanimod) is indicated for the treatment of moderately to severely active ulcerative colitis (UC)modulator. If CM is suspected, ZEPOSIA should be suspended until cryptococcal infection has been excluded. in adults. If CM is diagnosed, appropriate treatment should be initiatedIMPORTANT SAFETY INFORMATION ProgressiveMultifocalLeukoencephalopathy(PML)isanopportunisticviralinfectionofthebrainthat Contraindications: typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability. Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transientPML has been reported in patients treated with S1P receptor modulators and other UC therapies and has ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure orbeen associated with some risk factors. If PML is suspected, withhold ZEPOSIA and perform an appropriate have a presence of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome,diagnostic evaluation. If con rmed, treatment with ZEPOSIA should be discontinuedor sino-atrial block, unless the patient has a functioning pacemaker In the UC clinical studies, patients who received ZEPOSIA were not to receive concomitant treatment withPatients with severe untreated sleep apnea antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatmentPatients taking a monoamine oxidase (MAO) inhibitor of UC. Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk of Infections: ZEPOSIA may increase the susceptibility to infections. Life-threatening and rare fatal infectionsimmunosuppression.WhenswitchingtoZEPOSIAfromimmunosuppressivemedications,considerthe have occurred in patients receiving ZEPOSIA. Obtain a recent (i.e., within 6 months or after discontinuationduration of their effects and their mode of action to avoid unintended additive immunosuppressive effectsof prior UC therapy) complete blood count (CBC) including lymphocyte count before initiation of ZEPOSIA.Use of live attenuated vaccines should be avoided during and for 3 months after treatment with ZEPOSIA. If Delay initiation of ZEPOSIA in patients with an active infection until the infection is resolved. Considerlive attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ZEPOSIAinterruption of treatment with ZEPOSIA if a patient develops a serious infection. Continue monitoring forPlease see additional safety information and Brief Summary of the Prescribing Information and infections up to 3 months after discontinuing ZEPOSIA. Medication Guide on the following pages.Cosmos Communications 1 Q1 Q2C M Y K ej44878b 07.14.21 133 1PREPARED BY11561844 US Branded Journal Ad A SIZE M25FR Cosmos Communications 1 Q1 Q2C M Y K ej44878a 07.13.21 133 1Job info Images FontsSpecial InstructionsDate: 7-1-2021 6:46 PM BMS_A071452_4C.tif (CMYK; 975 ppi; 30.74%;Montserrat (Bold, Regular, Italic), Neuropoliti- 3 PG 4/C ad: spread followed by single page-Client: BMS 687.2MB), Z_banner.ai (140.04%, 153.3%;calCustom (Regular ) Create 5 pgs blank or greeked Brief Summary Product: OZANIMOD US 44KB), ZEPOSIA_US_RM_OD_CMYK_FC_Pos. pages for nowBuild mech to final A size specs Client Code: 2084-US-2101341 ai (32.7%, 30.28%; 72KB), ICONS_v01_CMYK.aiAdditional InformationWF Issue # 8935889 (47.01%; 1.1MB) NoneReleasing as: Native FilesFinal Size: NoneFinishing: NoneGutter: None Inks Additional Comments for SizingColors: 4/C & B/WCyan, Magenta, Yellow, Black Single page 4/C specs: 8.25in x 10.875inLIVE: 7.25in*x 10in (.50 from trim edge)BLEED: 8.50in Team x 11.375inProducer: NoneAD: Phoebe FelizAE: Leah OKeeffe Scale: 1"= 1"QC: None Bleed 17" w x 11.375" h17" w x 11.375" hProduction: Debi Post Trim/Flat 16.5" w x 10.875" h16.5" w x 10.875" hDigital Artist: Eberhart, Thomas (NYC-FCB) Live/Safety 15.5" w x 9.875" h15.5" w x 9.875" h FR Spellcheck:NonePath: PrePress:BMS:OZANIMOD:11561844:11561844_US_Branded_Ad_M25FR.indd_ _'